Zilberberg, J., et al.
Zilberberg, J., et al. “Personalized immunotherapeutic platform with evidence of clinical activity in glioblastoma (IGV-001) protects mice against other lethal solid tumor challenges.” Presented at AACR 2022.
Zilberberg, J., et al. “Personalized immunotherapeutic platform with evidence of clinical activity in glioblastoma (IGV-001) protects mice against other lethal solid tumor challenges.” Presented at AACR 2022.